Noxilizer

Executive Summary

Noxilizer, Inc. is a privately held medical technology company based in Baltimore, Maryland, that specializes in ultra-low temperature nitrogen dioxide (NO2) gas sterilization systems and services. Founded in 2019, the company’s proprietary technology operates between 10°C and 30°C, enabling effective surface sterilization of temperature-sensitive pharmaceutical, biotech, and medical device products without the heat or toxic residues associated with traditional methods like ethylene oxide (EtO) or gamma irradiation. Noxilizer sells its sterilization equipment to manufacturers and also offers contract sterilization services, positioning itself as a flexible solution for the growing demand for safer, more compatible sterilization alternatives. With increasing regulatory scrutiny on EtO and the expansion of advanced therapeutics (e.g., gene therapies, biologics, drug-device combinations), Noxilizer’s platform is well-aligned to capture market share in the medical and pharmaceutical sterilization market. The company’s go-to-market strategy leverages both capital equipment sales and recurring service revenue, which provides diversification and customer stickiness. While Noxilizer operates in a competitive landscape that includes established players such as Steris and J&J’s ASP, its low-temperature, fast-cycle NO2 process offers distinct advantages for heat- and moisture-sensitive products. Key near-term growth drivers include securing additional FDA clearances for specific device types, expanding contract sterilization capacity, and forming strategic partnerships with pharmaceutical manufacturers. However, as a private company with limited public financial disclosure, the exact commercial traction and valuation remain opaque. Overall, Noxilizer represents a promising but early-stage opportunity in the critical field of medical sterilization.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Sterilization of Additional Medical Device Categories70% success
• 2026Strategic Partnership or Supply Agreement with a Top-20 Pharmaceutical Company50% success
• Q4 2026Completion of Series B or Series C Funding Round to Scale Contract Sterilization Capacity65% success